ClinicalTrials.gg
Active, not recruitingNCT06465563Updated May 29, 2026

SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer

A Phase 2 interventional study of SHR-8068 and Adebrelimab in Biliary Tract Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies in Biliary Tract Neoplasms with a site in China — 93 open to participants now, 111 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.

Enrollment
57th of 157
93 · median 62
Started
2024
with 23 others
Phase 2
94 of 176
52 open now
Primary completion
2026-12
later than 37 of 110 live
Registered
103rd of 176
by date
Lead sponsor
4 of 176
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Among the 176 studies in Biliary Tract Neoplasms with a site in China, this one is the 57th largest by enrollment of the 157 interventional ones that give a count, is one of 24 that started in 2024, is one of 94 in phase 2, reaches primary completion later than 37 of the 110 other live ones, and was the 103rd registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

93 of the 176 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Biliary Tract Neoplasms with a site in China, or all of them as a file.
02

Study summary

Cohort A and B: This cohort aims to evaluate the efficacy and safety of SHR-8068 and Adebrelimab in combination with Cisplatin plus Gemcitabine (CisGem), compared with Adebrelimab in combination with CisGem, as first-line treatment in patients with Advanced Biliary Tract cancer. Cohort C: This cohort aims to evaluate the efficacy and safety of SHR-8068 and Adebrelimab and Bevacizumab in combination with Cisplatin Plus Gemcitabine (CisGem) as first-line treatment in patients with Advanced Biliary Tract cancer.

03

Conditions studied

  • Biliary Tract Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18\~75 years old, both male and female;
  2. or cytologically confirmed unresectable locally advanced, or recurrent/ biliary tract adenocarcinoma (including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma);
  3. Has not received prior systemic anti-tumor therapy;
  4. At least one based on v1.1 criteria;
  5. PS score: 0-1 points;
  6. Expected survival period ≥ 3 months;
  7. Adequate organ function;
  8. Must take one medically approved measure;
  9. Patients voluntarily joined the study and signed .

Exclusion criteria

Exclusion Criteria:

  1. history or concurrently has other solid tumor;
  2. Patients with liver tumor burden greater than 50% of total liver volume;
  3. History of previous hepatic encephalopathy;
  4. Patients with biliary obstruction , at risk of biliary tract infection;
  5. Patients with undergone major surgical treatment within 4 weeks before randomization;
  6. Patients with any active, known or suspected disorder;
  7. Patients with active pulmonary tuberculosis;
  8. Patients with known history of or active hepatitis;
  9. Untreated central nervous system ;
  10. Pleural or peritoneal effusion with clinical symptoms;
  11. Patients with poorly controlled cardiac clinical symptoms or disease;
  12. Patients with abnormal coagulation function and bleeding tendency;
  13. Known allergic reaction to Adalimumab or other monoclonal antibodies, or to the trial drug;
  14. Patients with other potential factors that may affect the study results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Arm A: SHR-8068, Adebrelimab, Cisplatin and Gemcitabine

    Drug: SHR-8068 · Drug: Adebrelimab · Drug: Cisplatin · Drug: Gemcitabine

  • Experimental
    Arm B: Adebrelimab, Cisplatin and Gemcitabine

    Drug: Adebrelimab · Drug: Cisplatin · Drug: Gemcitabine

  • Experimental
    Arm C: SHR-8068, Adebrelimab, Bevacizumab, Cisplatin and Gemcitabine

    Drug: SHR-8068 · Drug: Adebrelimab · Drug: Cisplatin · Drug: Gemcitabine · Drug: Bevacizumab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants with Complete Response (CR) or Partial Response (PR), as determined by the investigator according to RECIST v1.1.

    Time frame: From Randomization to the first occurrence of disease progression or initiation of new anti-tumor therapy (up to approximately 14 months)

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants with Complete Response (CR), Partial Response (PR) or Stable Disease (SD), as determined by the investigator according to RECIST v1.1.

    Time frame: From Randomization to the first occurrence of disease progression or initiation of new anti-tumor therapy (up to approximately 14 months)] (up to approximately 14 months)

  2. Progression-Free-Survival (PFS)

    PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first).

    Time frame: From randomization to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first) (up to approximately 14 months)

  3. Duration of Response (DoR)

    DoR is defined as the time from the first occurrence of a confirmed objective response to disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first).

    Time frame: From the first occurrence of a confirmed objective response to disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first) (up to approximately 14 months)

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 20, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06465563
Responsible party
Sponsor
First posted
Jun 20, 2024
Start date
Jul 1, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adebrelimab

Start the discussion